Independent Testing Of SANDD Pro™ for IEC And UL Certification Successfully Completed

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

RedHawk Holdings Corp. has announced they have successfully completed the independent laboratory testing of its newly designed SANDD Pro™ needle incineration device. Testing was performed by Intertek PLC (“Intertek”) to independently confirm the SANDD Pro™ meets the safety requirements of both International Electrotechnical Commission 61010-1 and Underwriter Laboratories 61010-1 for the United States, Canada, and Europe; Certification Bodies Scheme for the United States, Canada, and Europe; and, Electrical Testing Laboratories Listing for the United States and Canada.

Intertek is a leading total quality assurance provider to industries worldwide with more than 46,000 employees in 1,000 locations in over 100 countries based in the UK. Intertek testing ensures products meet quality, health, environmental, safety, and social accountability standards for virtually any market around the world. Intertek holds extensive worldwide accreditations and recognitions.

“The successful independent lab testing of our newly designed SANDD Pro™ needle incineration unit was the final step before commencing production,” commented G. Darcy Klug, RedHawk’s Chairman, and Interim Chief Executive Officer. “We can now begin the production process and we expect to launch sales and leasing of theSANDD Pro™ needle incineration device, coupled with certain bio-hazard waste disposal services, during the summer of 2020.”

The SANDD Pro™ is capable of incinerating hypodermic needles 18-gauge and higher, up to 8 inches in length. The SANDD Pro™ technology also features a separate portable, rechargeable, lithium-ion battery-operated unit (the “SANDD Pro™ – Portable”) capable of incinerating as many as 300 needles, ranging in gauges as thick as 21 gauge and lengths up to 8″ on a single charge. RedHawk believes the SANDD Pro™ – Portable will be ideal for field use by first responders, home health care nurses, veterinarians, and home use injectors. The SANDD Pro™ is both FDA approved and OSHA compliant.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.